Literature DB >> 24494530

IgG antibodies in patients with pemphigus vulgaris before and after diagnosing with immunofluorescence.

Hamideh Azimi1, Jafar Majidi2, Rasul Estakhri3, Mohamad Goldust4.   

Abstract

Pemphigus is defined as a group of chronic self-immune vesicular diseases histologically recognized by inter-epidermic vesicles resulting from acantholysis. The aim of this study was to evaluate the precipitant and circulative IgG antibodies in patients with pemphigus vulgaris before and after treating with immunofluorescence. Sixty-two patients (34 females and 28 males) with clinically and pathologically confirmed P.V. were studied prospectively over a one year period of time during which direct and indirect immunofluorescent tests were performed before and after treatment. They had mild or moderate forms of disease. All patients received prednisolon 1-2 mg/kg/day and Azathioprine 2-3 mg/kg/day or methylpredisolon (1 g day(-1) for 4 days) and cyclophosphamide (500 mg/first day) pulse therapy due to general condition. Thirty- four females and 28 males enrolled, the mean age were 39.5 years (SD = 12.7). Before treatment, 10 and 52 cases were positive for skin depositing + or ++) and circulatory IgG (1/20 -1/60), respectively. Two to 3 month later, 37 were IgG positive with titers 1/20 to 1/160. The correlation between circulatory IgG before and after treatment was weakly positive (p = 0.05, r = 0.415). In the present study, treatment methods used for patients suffering from pemphigus vulgaris were not successful in significantly decreasing the circulative autoantibodies levels.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24494530     DOI: 10.3923/pjbs.2013.589.592

Source DB:  PubMed          Journal:  Pak J Biol Sci        ISSN: 1028-8880


  1 in total

1.  Immunohistochemistry for Immunoglobulin G4 in the Diagnosis of Pemphigus.

Authors:  Mitra Heidarpour; Parvin Rajabi; Elnaz Babaei Pour; Emad Fayyazi
Journal:  Indian J Dermatol       Date:  2019 Jul-Aug       Impact factor: 1.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.